Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
- 1 September 2006
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 16 (s2) , 543-548
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast CancerClinical Cancer Research, 2005
- Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt ActivityClinical Cancer Research, 2004
- New targets for therapy in breast cancer: Farnesyltransferase inhibitorsBreast Cancer Research, 2004
- Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell LinesBreast Cancer Research and Treatment, 2003
- The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivoCancer Chemotherapy and Pharmacology, 2000
- Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.Endocrine-Related Cancer, 1999
- Raf gets it togetherNature, 1996
- Aberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Research and Treatment, 1995
- Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.Molecular and Cellular Biology, 1994